Entity
  • SpyBiotech

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    286 2,079
  • Activities

  • Technologies

  • Entity types

  • Location

    Oxford Business Park, Garsington Rd, Oxford OX4 2JZ, UK

    Oxford

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 23

  • Engaged corporates

    3
    2 1
  • Added in Motherbase

    6 years, 1 month ago
Description
  • Value proposition

    Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide

    SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.

    SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy.

    The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.


    Vaccine Development

  • Homepage - SpyBiotech

    SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases.

  • https://spybiotech.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Oxford University Innovation
Oxford University Innovation
Research, Financial Services
Oxford University Innovation
Research, Financial Services
Other

22 May 2024


Oxford Science Enterprises
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Capitalistic
Not partnership
Not event

15 Feb 2021

30 Apr 2024



Financial Times
Financial Times
Media, Newspaper Publishing
Financial Times
Media, Newspaper Publishing
Other

30 Sep 2021


Similar entities
Loading...
Loading...
Social network dynamics